 |
|
|
| |
Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage Regimen in NS5A Inhibitor-Experienced Patients With Genotype 1-6 Infection: The Phase 3 POLARIS-1 Study
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Marc Bourlière1, Stuart C. Gordon2, Alnoor Ramji3, Natarajan Ravendhran4, Tram T. Tran5, Robert H. Hyland6, Jie Zhang6, Hadas Dvory-Sobol6, Luisa M. Stamm6, Diana M. Brainard6, G. Mani Subramanian6, John G. McHutchison6, Ziad H. Younes7, Michael P. Curry8, Eugene R. Schiff9, K. Rajender Reddy10, Michael P. Manns11
1Hospital Saint Joseph, Marseille, France; 2Henry Ford Health System, Detroit, MI; 3St. Paul's Hospital, Vancouver, British Columbia, Canada; 4Digestive Disease Associates, Catonsville, MD; 5Cedars-Sinai Medical Center, Los Angeles, CA; 6Gilead Sciences, Inc., Foster City, CA; 7Gastro One, Germantown, TN; 8Beth Israel Deaconess Medical Center, Boston, MA; 9University of Miami, Miami, FL; 10University of Pennsylvania, Philadelphia, PA; 11Hannover Medical School, Hannover, Germany
|
| |
|
|
|
|
|
